Versant Capital Management’s Dyne Therapeutics DYN Stock Holding History

Versant Capital Management’s Portfolio DYN Stock Details DYN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$13.8K	Hold	859	–	–	﹤0.01%	2139
2026 Q2	$19.1K	Hold	859	–	–	﹤0.01%	1951
2026 Q1	$15.6K	Hold	859	–	–	﹤0.01%	1938
2025 Q4	$16.8K	Hold	859	–	–	﹤0.01%	1743
2025 Q3	$10.9K	Buy	859 +815	+1,852%	+$9.3K	﹤0.01%	1904
2025 Q2	$419	Sell	44 -239	-84%	-$2.63K	﹤0.01%	2559
2025 Q1	$2.96K	Buy	+283	New	+$4.05K	﹤0.01%	2206

Other funds holding DYN

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Fiera Capital (Canada) Montreal, Quebec, Canada $25.3B AUM 15.9% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 24.61% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $13.5B AUM 16.58% 1-Year Est. Return

Fisher Asset Management Camas, Washington $348B AUM 26.9% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

ALPS Advisors Denver, Colorado $21.8B AUM 17.58% 1-Year Est. Return

Versant Capital Management's DYN Position: Q3 2026 in Review

Versant Capital Management held its Dyne Therapeutics (DYN) position steady in Q3 2026 at 859 shares worth $13.8K. The position accounts for ﹤0.01% of the portfolio, ranked #2139.

Versant Capital Management first reported a position in DYN in Q1 2025 and has held it in 7 quarters since. The position peaked at $19.1K in Q2 2026. 88 funds tracked by Wall St. Rank hold DYN as of Q3 2026.

Versant Capital Management held 859 shares of Dyne Therapeutics worth $13.8K as of Q3 2026.
Versant Capital Management left its Dyne Therapeutics share count unchanged in Q3 2026.
Dyne Therapeutics made up ﹤0.01% of Versant Capital Management's portfolio in Q3 2026, its #2139 holding.
Versant Capital Management first reported a position in Dyne Therapeutics in Q1 2025 and has held it in 7 quarters since.
Versant Capital Management's Dyne Therapeutics position peaked at $19.1K in Q2 2026.
88 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q3 2026.

Based on Versant Capital Management's 13F filing for Q3 2026, filed 2 Oct 2026.